Hepatopathy following irradiation and adriamycin.
This report describes two cases of hepatopathy following irradiation and adriamycin at doses and volumes of irradiation ordinarily considered within the tolerance of hepatic function. In one case fatal hepatopathy followed 2400 rad/17 fractions/28 days to the entire liver with preceding and concurrent adriamycin. In the second case moderate clinical changes occurred after treatment in which much of the right lobe of the liver was shielded following 2500 rad/23 fractions/32 days with adriamycin administered before, during, and after irradiation. The locally enhancing effects of adriamycin on hepatic tolerance to irradiation are discussed.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D008107:Liver Diseases / Q000209:etiology*; D008297:Male; D010051:Ovarian Neoplasms / Q000628:therapy; D011832:Radiation Injuries / Q000209:etiology*; D011879:Radiotherapy Dosage
D000970:Antineoplastic Agents; D004317:Doxorubicin